You are here: Home » PTI Stories » National » News
Business Standard

AstraZeneca Pharma launches anti-diabetic tablet Xigduo XR

Press Trust of India  |  New Delhi 

Pharma India today said it has launched an anti-diabetic tablet 'Xigduo XR' used for the treatment of type 2 in adults.

The drug is a product of Group and is approved in 61 countries to date including the US, EU and

It is a combination of metformin and dapagliflozin, an inhibitor of sodium-glucose cotransporter 2, the company said in a statement.

Xigduo XR is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 mellitus.

"We believe this novel once-daily combination therapy of dapagliflozin and metformin can address an unmet medical need by offering a comprehensive and convenient treatment option for the Indian phenotype patient," Pharma India said.

The combination of drug is backed by the XR (extended release) technology which provides 24-hour sugar control.

Eight in ten Indians display a characteristic feature of the Indian Phenotype (greater degree of central body obesity, and characteristic dyslipidemia) making them highly vulnerable to developing the nexus of type 2 diabetes, and hypertension, the company said.

Xigduo XR is available in multiple dosage strengths of dapagliflozin and metformin HCI extended-release including 10/500 mg and 10/1000 mg.

(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

First Published: Wed, February 14 2018. 17:35 IST